2019
DOI: 10.1038/s41598-019-52909-9
|View full text |Cite
|
Sign up to set email alerts
|

Surrogates for myocardial power and power efficiency in patients with aortic valve disease

Abstract: We aimed to assess surrogate markers for left ventricular (LV) myocardial power and efficiency in patients with isolated aortic stenosis (AS) and combined stenosis/regurgitation (AS/AR). In AS (n = 59), AS/AR (n = 21) and controls (n = 14), surrogates for LV myocardial power and circulatory/external myocardial efficiency were obtained from cardiac MRI. Median surrogate LV myocardial power was increased in AS, 7.7 W/m2 (interquartile range 6.0–10.2; p = 0.010) and AS/AR, 10.8 W/m2 (8.9–13.4; p < 0.001) when com… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
19
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(20 citation statements)
references
References 44 publications
1
19
0
Order By: Relevance
“…As such, there were previous studies that attempted to measure MEf using standalone echocardiographic or cardiac MRI techniques without directly measuring mVO 2 but estimating it through LV wall stress. 26) 27) Others have used surrogate markers such as cardiac power/mass index to estimate MEf, which is conceptually similar to the formula used in the present study but excludes mVO 2 since it could not be directly measured with echocardiography. 28) Present methodology gives MEf as a percentage using the same formula employed by combined echocardiography/PET studies and allows an indirect comparison of findings between studies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…As such, there were previous studies that attempted to measure MEf using standalone echocardiographic or cardiac MRI techniques without directly measuring mVO 2 but estimating it through LV wall stress. 26) 27) Others have used surrogate markers such as cardiac power/mass index to estimate MEf, which is conceptually similar to the formula used in the present study but excludes mVO 2 since it could not be directly measured with echocardiography. 28) Present methodology gives MEf as a percentage using the same formula employed by combined echocardiography/PET studies and allows an indirect comparison of findings between studies.…”
Section: Discussionmentioning
confidence: 99%
“…This is also true for other standalone methods which does not directly measure mVO 2 but estimate it indirectly through equations. 26) 27) Nonetheless, we consider that a noninvasive, “single imaging modality” approach to calculate MEf, either using the methodology described in the present study or with other methods described in the literature, has the potential to bring MEf out of the research realm and make it an alternative and more integrated measure of LV function in the clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…The temporal solution was 25 timesteps for 4D flow measurements and 30 timesteps for 2D flow measurements. We could show that 4D flow measurements with 25 timesteps are a feasible alternative to flow measurements with higher temporal solution in a prior study [ 15 ].…”
Section: Methodsmentioning
confidence: 99%
“…The ratio of the power needed to pump a given blood volume against a given afterload (circulatory power, CP) to the power used by the heart to perform one heartbeat (Left ventricular myocardial power, LVMP) is described as circulatory efficiency (CircE). LVMP was defined as the surrogate power of the LV to perform one heartbeat since the applied method is an estimation [ 15 , 19 ]: …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation